Scientist in Biopharmaceutical Purification

Responsibilities:

- The individual is responsible for vaccine downstream process technology transfer, engineering scale-up, process optimization from bench to large scale for a number of production processes using E. coli and/or mammalian cell culture technology.
- The individual will work with colleagues to conduct purification of recombinant proteins, or monoclonal antibodies, or immunotoxins, or viral vectors.
- The individual will train junior staffs in technical skills and GMP compliance.
- The group will accept lab scale process through technology transfer and scale-up the process to production scale with optimization in large scale production.
- The group will support analytical development and product characterization.

Request:

- Minimum 5 years biopharmaceutical industrial experiences after Ph.D. training in related fields of biochemical engineering, chemical engineering, protein engineering, biochemistry, and/or biological sciences.
- Must have CGMP experiences in biologics.
- Previous leadership in downstream biological production is appreciated.
- Previous experiences in international biopharmaceutical industry is a plus.
- Excellent communication skill both in Chinese and in English is required.

主要职责：
1. 负责疫苗产品下游的技术转移、工程放大及使用到大肠杆菌和/or哺乳动物细胞培养技术的多项生产工艺的工艺优化（从实验室到大规模生产）
2. 负责对重组蛋白、单克隆抗体、抗毒素或病毒载体进行纯化；
3. 负责依照行GMP的相关要求及标准对初级员工的进行相关的技术培训及其他培训；
4. 确保团队通过技术转移和工程放大接收并熟悉实验室规模的操作流程，并实现大规模生产的工艺优化；
5. 确保团队能够支持分析开发及产品特性的鉴定；

具体要求：
1. 生物工程、化学工程、生物化学、细胞生物学、工程发酵等生物相关专业博士或同等学历；需5年以上生物制药企业相关工作经验；
2. 必须具备生物制剂cGMP相关工作经验；熟知cGMP相关知识及要求标准；
3. 拥有生物制药生产上游管理经验者优先；拥有国际生物制药企业相关工作经验者优先；
4. 具有流利的英语口语和读写能力。
Scientist in Mammalian Cell Culture

Responsibilities:

- responsible for vaccine upstream process technology transfer, engineering scale-up,
- responsible for process optimization from bench to large scale for a number of production processes using mammalian cell culture technology.
- The individual will work with colleagues to conduct mammalian cell culture in producing monoclonal antibodies, cytokines, IgG fusion proteins.
- train junior staffs in technical and GMP compliance.
- The group will accept lab scale process through technology transfer and scale-up the process to production scale with optimization in large scale production.
- The group will conduct production harvest to support downstream production.

Request:

- Minimum 5 years biopharmaceutical industrial experiences after Ph.D. training in related fields of biochemical engineering, chemical engineering, biochemistry, cell biology, industrial fermentation, and/or biological sciences. Must have CGMP experiences in biologics.
- Previous leadership in upstream biological production is appreciated.
- Previous experiences in international biopharmaceutical industry is a plus. Excellent communication skill both in Chinese and in English is required.

主要职责:

1. 负责疫苗产品上游的工艺技术转移、工程放大；
2. 负责使用到脯乳动物细胞培养技术的工艺优化（从实验室研发到大规模生产）；
3. 负责哺乳动物细胞培养，及生产单克隆抗体、细胞因子及 IgG 融合蛋白
4. 依照 GMP 的相关要求及标准对初级员工的进行技术培训及其他培训；
5. 确保团队通过技术转移和工程放大接收并熟悉实验室规模的操作流程，并实现大规模生产的工艺优化；
6. 进行产品收集，用以支持下游生产的相关工作；

具体要求:

1. 生物工程、化学工程、生物化学、细胞生物学、工程发酵等生物相关专业博士或同等学历；需 5 年以上生物制药企业相关工作经验；
2. 必须具备生物制剂 cGMP 相关工作经验；熟知 cGMP 相关知识及要求标准；
3. 拥有生物制药生产下游管理经验者优先；拥有国际生物制药企业相关工作经验者优先；
4. 具有流利的英语口语和读写能力
International Registration and Clinical Trial Senior Specialist
Responsibilities:

- Be responsible for writing, translation and submission of the application documentations in accordance with international registration strategy and the requirement of regulatory agency. Guarantee the accuracy and reliability of the application documentations.
- Submit the applications according to the procedures. Cooperate with the regulatory agencies or CRO companies to handle relevant procedures. Guarantee to complete the applications in timely manner.
- Communicate and coordinate with external cooperation companies, to ensure that the project is carried out on schedule;
- Coordinate and follow-up on related work of registration in the international projects. Ensure the projects are carried out on schedule;
- Communicate with the partners or subcontractors in international clinical trials, to provide active communication and summarize the project progress regularly. Ensure the projects are carried out on schedule;
- Comply with the internal rules and regulations. Be able to finish work in accordance with company requirements, and be able to complete other work assigned by superiors and company.

Request:

- Master degree and major background in medicine, pharmacy, biology, chemistry, etc. Experience of study abroad is preferred.
- Three years’ work experience in vaccine development, registration or clinical trials
- CET-6 and above
- Be able to access relevant literature references in English, draft and review reports and files in English independently;
- With good communication skills, clear verbal and written expression and be good at active communication;
- Be able to work independently, with strong collective awareness and good team spirit;
- Acknowledge of vaccine production process and vaccine GMP regulations.
About CanSinoBIO

CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide.

Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with now more than 600 employees, one approved vaccine for Ebola virus disease (Ad5-EBOV) and 16 vaccine candidates in the product pipeline. CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates.

Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed four key platform technologies, including adenovirus-based viral vector vaccine, conjugation, protein structure design and recombination as well as vaccine formulation technologies.

In addition, the company has in-licensed a number of new technologies and intellectual properties through collaborations with international research organizations and biotechnology companies. CanSinoBIO collaborates through partnerships with world-class academic centers or start-up companies that develop innovative technologies, to prepare the portfolio of the next decades and ensure sustainable growth of the company.

CanSinoBIO is currently developing 16 vaccine candidates for 13 infectious disease areas, preventing meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Among these, Ad5-EBOV, the globally innovative Ebola virus disease vaccine, has received NDA (New Drug Application) approval in China in October 2017. The NDA applications of two meningococcal conjugate vaccines are under NMPA review. Moreover, Ad5-nCoV, the investigational vaccine against COVID-19 has been approved to enter into phase I clinical trial. At present, CanSinoBIO has seven vaccine candidates in the clinical trial stage or clinical trial application stage. There are also six pre-clinical vaccine candidates under development, including one combination vaccine candidate.

CanSinoBIO currently has a Research and Development Center with a floor space of approximately 120,000 square-feet as well as a 380,000 square-feet commercial manufacturing campus, which is designed, qualified and operated according to international cGMP standards (FDA, EU, WHO and China). The GMP pilot plants located in the R&D center have passed EU QPs’ audits. The annual bulk production capacity of the current facilities can reach approximately 70 million to 80 million doses, which will be capable of supporting our commercialization plans for our near-commercial vaccine candidates.

Vaccination is an essential part of effective disease control and prevention. CanSinoBIO is committed to make innovative and high quality vaccines accessible to people all over the world thus empower people to pursue healthy and better life.